首页期刊导航|四川生理科学杂志
期刊信息/Journal information
四川生理科学杂志
四川生理科学杂志

周黎明

季刊

1671-3885

shenglizazhi@163.com

028-85501278

610041

四川成都人民南路三段17号四川大学华西五教学楼

四川生理科学杂志/Journal Sichuan Journal of Physiological Sciences
查看更多>>本刊综述国内外最新生理科学研究动态及进展；报道有价值的实验结果和先进的实验方法；介绍医学教学的经验方法；探索教学改革的思路，评价新药在临床使用情况，指导临床安全合理用药，加强会员之间的交流与提高。
正式出版
收录年代

    Actionable Genotypes and Their Association with Life Span in Iceland

    Brynjar O Jensson
    857页
    查看更多>>摘要：Background:In 2021,the American College of Medical Genetics and Genomics(ACMG)recommended reporting actionable genotypes in 73 genes associated with diseases for which preventive or therapeutic measures are available.Evaluations of the association of actionable genotypes in these genes with life span are currently lacking.Methods:We assessed the prevalence of coding and splice variants in genes on the ACMG Secondary Findings,version 3.0(ACMG SF v3.0),list in the genomes of 57,933 Icelanders.We assigned pathogenicity to all reviewed variants using reported evidence in the ClinVar database,the frequency of variants,and their associations with disease to create a manually curated set of actionable genotypes(variants).We assessed the relationship between these genotypes and life span and further examined the specific causes of death among carriers.Results:Through manual curation of 4405 sequence variants in the ACMG SF v3.0 genes,we identified 235 actionable genotypes in 53 genes.Of the 57,933 participants,2306(4.0％)carried at least one actionable genotype.We found shorter median survival among persons carrying actionable genotypes than among noncarriers.Specifically,we found that carrying an actionable genotype in a cancer gene was associated with survival that was 3 years shorter than that among noncarriers,with causes of death among carriers attributed primarily to cancer-related conditions.Furthermore,we found evidence of association between carrying an actionable genotype in certain genes in the cardiovascular disease group and a reduced life span.Conclusions:On the basis of the ACMG SF v3.0 guidelines,we found that approximately 1 in 25 Icelanders carried an actionable genotype and that carrying such a genotype was associated with a reduced life span.
      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普

    缺血性脑卒中患者应用DSA辅助下神经介入取栓术的疗效分析

    朱军武
    858-860页
    查看更多>>摘要：目的:探究数字减影血管造影(Digital subtraction angiography,DSA)辅助下神经介入取栓术治疗缺血性脑卒中的效果.方法:选择 2019年 10 月至2022 年10 月本院收治的缺血性脑卒中患者 130 例作为研究对象.随机将患者分为对照组和观察组,各 65 例.对照组接受静脉溶栓治疗;观察组实施DSA辅助下神经介入取栓术治疗.在术后 1 w,分析对比两组的治疗效果.结果:观察组总有效率高于对照组(P＜0.05).治疗前,两组国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)无显著差异(P＞0.05).治疗后,观察组NIHSS评分低于对照组(P＜0.05).观察组血管再通率高于对照组(P＜0.05).结论:对缺血性脑卒中采用DSA辅助下神经介入取栓术治疗能改善患者的神经功能,提高其血管再通率,提高治疗效果.

    缺血性脑卒中DSA神经介入取栓术总有效率神经功能血管再通率

      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普

    -PRCD联合APD对急性重症胰腺炎患者预后的影响

    王保雨张会杰陈国营
    861-863页
    查看更多>>摘要：目的:分析超声引导经皮腹膜后穿刺置管引流(Percutaneous retroperitoneal catheter drainage,PRCD)联合腹腔穿刺引流(Abdominal paracentesis drainage,APD)对急性重症胰腺炎(Severe acute pancreatitis,SAP)患者预后的影响.方法:回顾性分析 2021 年 03 月至 2022 年 09 月期间本院急诊科诊治的 92 例SAP患者临床资料,依据治疗方式不同分为对照组(单纯PRCD,49 例)和研究组(PRCD联合APD,43 例).治疗前、治疗后(48～72 h)分别采用酶速率法、血液分析仪计数法、酶联免疫吸附试验测定两组血淀粉酶、白细胞计数(White blood cell,WBC)、C反应蛋白(C reactive protein,CRP)水平,同时记录两组治疗情况、临床相关指标以及感染情况.结果:研究组的血淀粉酶、WBC、CRP水平均显著低于对照组(P＜0.05).研究组体温恢复正常、抗生素使用及重症监护室(Intensive care unit,ICU)住院时间均显著短于对照组,医疗费用显著低于对照组(P＜0.05).研究组多器官功能衰竭、急性呼吸窘迫综合征、多器官功能障碍综合征发生率、死亡率均显著低于对照组(P＜0.05);研究组的并发感染率与对照组比较差异无统计学意义(P＞0.05).结论:超声引导下PRCD与APD联合可有效改善SAP患者的预后,不增加其感染发生风险.

    超声引导经皮腹膜后穿刺置管引流腹腔穿刺引流急性重症胰腺炎预后

      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普

    Systemic lupus erythematosus

    Alberta Hoi
    863页
      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普

    NCPAP,雾化吸入联合IHIG辅助治疗重症肺炎的作用分析

    许兆颖魏晓丽龚文品
    864-866页
    查看更多>>摘要：目的:探讨重症肺炎患者应用经鼻高流量正压通气(Nasal high flow positive pressure ventilation,NCPAP)、雾化吸入联合人免疫球蛋白(Human immunoglobulin,IHIG)辅助治疗的效果.方法:选取 2021 年 2 月至 2023年 2 月医院收治重症肺炎患者 82 例,采用随机数字表格法分为对照组和观察组,每组各 41例.对照组接受常规治疗,观察组在此基础上使用NCPAP+雾化吸入+IHIG联合治疗.分析对比两组的疗效,治疗前、治疗后 5 d以肺功能仪检测肺功能,酶联免疫法检测肿瘤坏死因子-α(Tumor Necrosis Factor-α,TNF-α)、内皮素(Endothelin-1,ET-1)水平.结果:观察组有效率高于对照组(P＜0.05).干预后,观察组的肺功能水平均显著优于对照组(P＜0.05).干预后观察组的TNF-α、ET-1 水平均显著低于对照组(P＜0.05).结论:重症肺炎NCPAP+雾化吸入+IHIG联合可提高疗效,改善肺功能,降低TNF-α与ET-1 表达.

    重症肺炎鼻高流量正压通气雾化吸入人免疫球蛋白

      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普

    Matching actions to needs:shifting policy responses to the changing health needs of Chinese children and adolescents

    Tian-Jiao Chen
    866页
      原文链接:
    • NETL
    • NSTL
    • 万方数据

    HPV、TCT检查在子宫颈癌前病变筛查中的价值分析

    南静王静
    867-869页
    查看更多>>摘要：目的:分析人乳头瘤病毒(Human Papilloma Virus,HPV)、宫颈液基细胞学检查(Thin-Cytologic Test,TCT)在子宫颈病变筛查中的临床价值.方法:选取 2020 年7 月至 2023 年7 月期间在本院进行子宫颈癌前病变筛查的疑似子宫颈癌前病变患者 2614例作为研究对象.所有患者均进行HPV与TCT检查,将病理学的检验结果作为本研究的金标准,比较HPV与TCT这两种检验方法的检查结果,分析HPV、TCT检查分别在子宫颈癌前病变早期筛查中的实际临床价值.结果:2614 例疑似子宫颈癌前病变患者中经病理检查,阳性检出率为 8.22%.HPV检查阳性检出率为 8.11%,与病理学检验结果间的Kappa值为 0.6855;经TCT检查阳性检出率为 2.98%,与病理学检验结果间的Kappa值为 0.4182;联合检查阳性检出率为 8.19%,与病理学检验结果间的Kappa值为0.7383;对子宫颈癌前病变诊断的检查灵敏度、特异度、准确度、阳性预测值和阴性预测值分别如下,HPV 检查为 69.77%、97.62%、95.33%、72.46%、97.30%;TCT检查为30.23%、99.46%、93.46%、83.33%、94.09%;联合检查为 74.88%、97.79%、95.91%、75.23%、97.75%;结论:HPV和TCT检查均适用于在早期子宫颈癌前病变的筛查,且其更加简单快捷,对患者的创伤较小,推荐在临床使用.

    人乳头瘤病毒宫颈液基细胞学检查子宫颈癌前病变早期筛查

      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普

    复方丙酸氯倍他索软膏辅助阿维A胶囊治疗寻常型银屑病的疗效

    王忠友
    870-872页
    查看更多>>摘要：目的:探讨复方丙酸氯倍他索软膏辅助阿维A胶囊治疗寻常型银屑病的疗效.方法:选取我院 2021年 1至2023 年1 月期间诊治的100 例寻常型银屑病患者作为研究对象.随机将患者分成对照组和观察组,每组各 50 例.对照组采用阿维A胶囊进行治疗;观察组采用复方丙酸氯倍他索软膏辅助阿维A胶囊治疗,两组均治疗 2 m.观察比较治疗 2 m后两组的临床疗效,生活质量以及治疗期间不良反应.结果:观察组治疗总有效率高于对照组(P＜0.05).与治疗前比较,两组患者皮肤病生活质量指数评分均下降,且观察组低于对照组(P＜0.05).两组不良反应比较未见明显差异(P＞0.05).结论:复方丙酸氯倍他索软膏辅助阿维A胶囊治疗寻常型银屑病,能提高临床疗效和生活质量,且不增加治疗期间的不良反应.

    寻常型银屑病阿维A胶囊复方丙酸氯倍他索软膏疗效不良反应

      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普

    Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

    Toni K Choueiri
    872页
    查看更多>>摘要：Background:Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial.Whether the results regarding overall survival from the third prespecified interim analysis of the trial would also favor pembrolizumab was uncertain.Methods:In this phase 3,double-blind,placebo-controlled trial,we randomly assigned(in a 1:1 ratio)participants with clear-cell renal-cell carcinoma who had an increased risk of recurrence after surgery to receive pembrolizumab(at a dose of 200 mg)or placebo every 3 weeks for up to 17 cycles(approximately 1 year)or until recurrence,the occurrence of unacceptable toxic effects,or withdrawal of consent.A significant improvement in disease-free survival according to investigator assessment(the primary end point)was shown previously.Overall survival was the key secondary end point.Safety was a secondary end point.Results:A total of 496 participants were assigned to receive pembrolizumab and 498 to receive placebo.As of September 15,2023,the median follow-up was 57.2 months.The disease-free survival benefit was consistent with that in previous analyses(hazard ratio for recurrence or death,0.72;95％confidence interval[CI],0.59 to 0.87).A significant improvement in overall survival was observed with pembrolizumab as compared with placebo(hazard ratio for death,0.62;95％CI,0.44 to 0.87;P = 0.005).The estimated overall survival at 48 months was 91.2％in the pembrolizumab group,as compared with 86.0％in the placebo group;the benefit was consistent across key subgroups.Pembrolizumab was associated with a higher incidence of serious adverse events of any cause(20.7％,vs.11.5％with placebo)and of grade 3 or 4 adverse events related to pembrolizumab or placebo(18.6％vs.1.2％).No deaths were attributed to pembrolizumab therapy.Conclusions:Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival,as compared with placebo,among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery.
      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普

    颈动脉超声在颈动脉斑块患者冠脉病变程度评估中的应用及对脑梗死发生风险的预测价值

    李伟静
    873-875页
    查看更多>>摘要：目的:探讨颈动脉超声在颈动脉斑块患者冠脉病变程度评估中的应用及对脑梗死发生风险的预测价值.方法:选取 2021 年 4 月至 2023年 4 月期间我院收治的冠心病(Coronary Heart Disease,CHD)患者 106 例作为研究对象,均行颈动脉超声及冠脉造影(Coronary Angiography,CAG)检查,根据CAG检查结果将患者分为单支病变组(n=38)、双支病变组(n=36)及三支病变组(n=32).比较三组及不同冠状动脉狭窄程度 Gensini 评分、患者颈动脉硬化等级评分、颈动脉斑块个数、易损斑块、非易损斑块,对比易损斑块患者与非易损斑块患者脑梗死发生率.结果:随病变支数增加、Gensini评分分值升高,CHD患者颈动脉硬化等级评分、颈动脉斑块个数、易损斑块人数占比呈上升趋势,非易损斑块人数占比呈下降趋势(P＜0.05);易损斑块患者脑梗死发生率高于非易损斑块患者(P＜0.05).结论:颈动脉超声对颈动脉斑块患者冠脉病变程度具有一定评估价值,并对其短期脑梗死发生风险具有一定预测价值,可作为临床判断病情、评估预后的有效检查方式.

    颈动脉超声颈动脉斑块冠脉病变脑梗死预测价值

      原文链接:
    • NETL
    • NSTL
    • 万方数据
    • 维普